Summary of ProMIS Neurosciences Conference Call Company Overview - **Company**: ProMIS Neurosciences (Ticker: PMN, Nasdaq) - **Focus**: Treatment of neurodegenerative diseases, primarily in the dementia space, including Alzheimer's, ALS, Parkinson's, and Lewy body dementia [2][3] Key Milestones - **Phase 1b Study**: Completed enrollment of 144 patients for PMN 310, a lead product for Alzheimer's disease, in December 2025 [3] - **Financing**: Successfully raised up to $175 million from a syndicate of investors, ensuring full funding through data readout [3][4] Upcoming Catalysts - **Data Release**: Interim analysis expected mid-2026, with final top-line results by the end of 2026 [4][23] - **Study Design**: Robust 12-month, placebo-controlled, randomized trial aimed at providing definitive answers regarding the efficacy of PMN 310 [4][21] EpiSelect Platform - **Proprietary Technology**: The EpiSelect platform allows for the design of highly selective antibodies targeting toxic oligomers of amyloid beta protein, differentiating ProMIS from competitors [8][10] - **Antibody Development**: PMN 310 is designed to selectively target toxic oligomers while avoiding binding to non-toxic forms, which is a significant advantage over other antibodies [12][16] Safety and Efficacy - **ARIA Management**: The company aims to achieve ARIA (Amyloid-related imaging abnormalities) rates similar to placebo (9%-14%), which would be a significant improvement over existing treatments [24][25] - **Safety Signals**: No treatment-related serious adverse events reported so far, with a lower than expected dropout rate, indicating strong patient enthusiasm [29][30] Biomarker Analysis - **Biomarkers**: A comprehensive panel of biomarkers will be used to assess treatment effects, including p-tau217, neurogranin, and NfL [32][33] - **Predictive Value**: p-tau217 has been identified as a strong predictor of clinical benefit, with expectations for a downward trend in biomarkers indicating drug efficacy [34][41] Future Pipeline and Partnerships - **Expansion Potential**: Successful proof of concept in Alzheimer's could lead to expedited entry into pivotal Phase 3 studies, bypassing Phase 2 trials [44] - **Interest from Pharma**: Ongoing discussions with pharmaceutical companies for potential partnerships, particularly for ALS and other neurodegenerative programs [44][45] Conclusion - **Transformational Year**: 2026 is positioned as a watershed year for ProMIS, with significant data expected that could transform treatment paradigms in Alzheimer's disease and other neurodegenerative conditions [46]

Summary of ProMIS Neurosciences FY Conference Call Company Overview - ProMIS Neurosciences is a publicly listed company on NASDAQ under the ticker PMN, focused on developing therapies for neurodegenerative diseases, particularly Alzheimer's disease [2][3] - The company is conducting a landmark 100-patient study with its lead monoclonal antibody, PMN310, targeting Alzheimer's disease [2][3] Core Points and Arguments Alzheimer's Disease Study - ProMIS is in the midst of a phase 1b study for Alzheimer's, with over 90% enrollment and data expected soon [3][26] - The study involves administering the drug over 12 months, with an interim analysis planned for mid-next year and final results expected by the end of next year [3][26] Unique Mechanism of Action - PMN310 selectively targets toxic oligomer forms of amyloid beta, which are believed to drive disease progression, rather than the plaque forms that previous therapies have targeted [4][5][7] - The company claims to be the only one with an antibody that selectively targets these toxic oligomers without binding to non-harmful forms [7][10] Differentiation from Competitors - ProMIS utilizes AI and advanced design techniques to create antibodies that specifically target misfolded proteins, a method that differs from competitors who have struggled with cross-reactivity to non-target forms [8][9][10] - Previous therapies targeting plaque have shown limited efficacy and significant side effects, such as ARIA (Amyloid-related imaging abnormalities) [6][12][15] Study Design and Expectations - The phase 1b study is designed to provide definitive answers regarding the drug's efficacy, with a focus on biomarkers, safety, and clinical signals [20][21] - The study aims to enroll 128 patients to ensure robust statistical outcomes, with a goal of moving directly to a phase 3 registration trial based on positive results [21][22] Biomarker Analysis - Key biomarkers being monitored include pTAU217, pTAU243, neurogranin, GFAP, SNAP25, and NFL, which are expected to show changes correlating with clinical outcomes [29][30] - The interim analysis will assess whether PMN310 is effectively engaging its target, with expectations of biomarker levels dropping if the drug is effective [30][31] Market and Strategic Insights - The company believes that reducing ARIA liability will significantly impact prescribing habits and patient confidence, enhancing revenue potential [36][39] - ProMIS has received interest from large pharmaceutical companies, indicating a positive outlook for partnerships and acquisitions in the Alzheimer's space [37][38] Future Outlook - The company anticipates that demonstrating improved safety and efficacy could shift the risk-benefit ratio favorably, benefiting both patients and shareholders [40][41] - ProMIS is positioned to potentially validate the oligomer hypothesis in Alzheimer's treatment, which could have significant implications for the industry [37][44] Other Important Content - The discussion highlighted the shift in understanding regarding the role of amyloid beta in Alzheimer's, moving away from plaque as the primary target to focusing on toxic oligomers [6][15] - The company emphasized the importance of a well-designed clinical study to provide credible evidence for its therapeutic approach [37][44]